Drugs Made In America Acquisition II Corp. DMII
$10.16
-$0.01-0.07%
NASDAQ
| 06/30/2026 | 03/31/2026 | 09/30/2025 | |||
|---|---|---|---|---|---|
| Net Income | 11,639.37% | 7,415.01% | -- | ||
| Total Depreciation and Amortization | -- | -- | -- | ||
| Total Amortization of Deferred Charges | -- | -- | -- | ||
| Total Other Non-Cash Items | -9,652.33% | -- | -- | ||
| Change in Net Operating Assets | -417.09% | -40.16% | -- | ||
| Cash from Operations | -6,542.31% | -925.00% | -- | ||
| Capital Expenditure | -- | -- | -- | ||
| Sale of Property, Plant, and Equipment | -- | -- | -- | ||
| Cash Acquisitions | -- | -- | -- | ||
| Divestitures | -- | -- | -- | ||
| Other Investing Activities | -- | -- | -- | ||
| Cash from Investing | -- | -- | -- | ||
| Total Debt Issued | -- | -- | -- | ||
| Total Debt Repaid | -- | -- | -- | ||
| Issuance of Common Stock | -- | -- | -- | ||
| Repurchase of Common Stock | -- | -- | -- | ||
| Issuance of Preferred Stock | -- | -- | -- | ||
| Repurchase of Preferred Stock | -- | -- | -- | ||
| Total Dividends Paid | -- | -- | -- | ||
| Other Financing Activities | -- | -- | -- | ||
| Cash from Financing | -- | -- | -- | ||
| Foreign Exchange rate Adjustments | -- | -- | -- | ||
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | ||
| Net Change in Cash | -6,542.31% | 3,575.00% | -- | ||